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1  | INTRODUC TION
Implant therapy is considered a predictable treatment with excellent 
long- term results. When teeth are lost, the alveolar process undergoes 
dimensional changes (Schropp, Wenzel, Kostopoulos, & Karring, 2003). 
The magnitude of these dimensional changes is clinically relevant for a 
comprehensive treatment planning. Furthermore, traumatic tooth loss 
during growth, multiple or longlasting edentulism, extensive bone and 
soft tissue resorption can hinder implant placement. Consequently, 
implant placement is often combined with augmentative procedures 
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Abstract
Objective: To assess the effect of platelet- rich plasma (PRP) on implant dentistry. The 
primary focused question was as follows: What are the clinical, histological, and radio-
graphic outcomes of PRP administration for bone regeneration and implant therapy?
Methods: A literature search was conducted involving three databases: MEDLINE, 
EMBASE and Cochrane database followed by a hand search of relevant scientific jour-
nals. Human studies using PRP for bone regeneration and implant therapy were consid-
ered and articles published up to December 31, 2017 were included. Eligible studies 
were selected based on the inclusion criteria, and quality assessments were conducted.
Results: In total, out from the 9,497 titles meeting the original search criteria, 22 
fulfilled the inclusion criteria and were chosen for data extraction. Among them were 
15 randomized controlled trials (RCT) and seven controlled clinical trials (CCT). 
Overall, the risk of bias was moderate to high. A total of seven studies showed supe-
rior outcomes when PRP was added during sinus floor elevation and five showed no 
superior outcome. Three studies found a significant advantage of PRP for alveolar 
bone regeneration and another three studies for soft tissue healing. Three studies 
reported on beneficial effects of PRP directly during implant placement while an-
other study failed to find significant differences. Due to the heterogeneity of study 
designs, no meta- analysis could be performed.
Summary and Conclusions: Despite the lack of consistent evidence supporting the 
clinical benefit of PRP in healthy patients, PRP might have a positive effect on wound 
healing and bone regeneration in compromised patients.
K E Y W O R D S
alveolar ridge preservation, bone regeneration, implant therapy, platelet-rich plasma, sinus 
floor elevation
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such as alveolar ridge preservation, guided bone regeneration, or sinus 
floor elevation (SFE) for an ideal prosthetic position of the implant.
Platelets play a fundamental role in the early stages of wound healing 
and bone regeneration by releasing growth factors and other molecules 
(Singer & Clark, 1999). Among the growth factors are platelet- derived 
growth factor, transforming growth factor- beta, but also cytokines, 
chemokines, and other molecules together targeting the various cell 
types involved in early wound healing and bone regeneration (Klinger 
& Jelkmann, 2002; Nurden, 2011). Activated platelets form aggregates 
with the fibrin- rich matrix as part of the hemostasis and thrombosis 
(Singer & Clark, 1999). One therapeutic concept is based on the assump-
tion that if physiologic concentrations of activated platelets are good, 
a supra- physiological concentration of activated platelets even better 
support the early stages of wound healing and bone regeneration.
Platelet- rich plasma (PRP) and platelet concentrate reached the 
field of dentistry in the 90s (Marx et al., 1998). Since then, slightly 
different protocols for preparing PRP have been established. In gen-
eral, anticoagulated blood is subjected to a first “soft” spin to sepa-
rate the plasma fraction from the erythrocytes. The plasma fraction 
is subjected to a second “hard” spin to separate the platelets from the 
platelet poor plasma (PPP). The platelet- pellet containing leukocytes 
is suspended in a lower volume of PPP and activated by thrombin 
and calcium. Through this dual centrifugation process, platelets are 
around 2 to 5- fold enriched compared to normal blood (Oudelaar, 
Peerbooms, Huis In ‘t Veld, & Vochteloo, 2018).
In recent years, systematic reviews have gathered evidence on 
the clinical impact of PRP on SFE (Lemos et al., 2016; Pocaterra et al., 
2016), alveolar ridge preservation (Del Fabbro, Corbella, Taschieri, 
Francetti, & Weinstein, 2014; Moraschini & Barboza, 2015) and peri-
odontal intrabony defects (Hou, Yuan, Aisaiti, Liu, & Zhao, 2016). 
The present systematic review is an update of the evidence for the 
use of PRP in implant therapy. It covers all aspects of implant ther-
apy, from pre- implantation measures to augmentative procedures 
and observations during the healing phase.
2  | MATERIAL AND METHODS
2.1 | Protocol development and eligibility criteria
This review was conducted according to the PRISMA (Preferred 
Reporting Items for Systematic Review and Meta- Analyses) state-
ment, conforming to which a detailed protocol was established 
(Liberati et al., 2009; Moher et al., 2015).
The focused question was formulated based on the PRISMA 
guidelines.
1. Population (P) = humans with lack of alveolar bone and/or need 
of implant therapy or tooth extraction.
2. Intervention (I) = use of PRP alone or in combination with a graft ma-
terial in guided bone regeneration techniques and implant therapy.
3. Comparison (C) = respective surgical procedure without PRP.
4. Outcome (O) = alveolar bone regeneration, soft tissue healing, 
graft resorption, osseointegration, implant stability and postop-
erative life quality issues such as pain and swelling.
5. Study design (S) = randomized, controlled clinical trials (CCTs), 
prospective CCTs, split-mouth or parallel arms.
The following PICOS question was raised: Is there any additional 
benefit of PRP on guided bone regeneration and implant therapy over 
traditional approaches in terms of clinical, histological and radiographic 
outcomes?
2.2 | Search strategy
An electronic search of three databases (MEDLINE, EMBASE, 
CENTRAL) was performed. Articles published up to December 31, 
2017 were considered. No language or time restrictions were ap-
plied in the search. However, only studies written in English were 
included for selection. An additional hand search was carried out 
encompassing the bibliographies of the included papers and other 
narrative and systematic reviews as well as in the following journals: 
Clinical Oral Implants Research, Clinical Implant Dentistry and Related 
Research, European Journal of Oral Implantology, Implant Dentistry, 
International Journal of Oral and Maxillofacial Implants, International 
Journal of Periodontics and Restorative Dentistry, Journal of Clinical 
Periodontology, Journal of Dental Research, Clinical Oral Investigations, 
Journal of Oral and Maxillofacial Surgery, Journal of Periodontology, 
Oral Surgery, Oral Medicine, Oral Radiology, Oral Pathology and 
Endodontics.
2.3 | Search terms
The electronic search strategy included terms related to the inter-
vention and used the following combination of key words, MeSH and 
Emtree terms: “osseointegration” OR “dental implants, single- tooth” 
OR “dental implants” OR “tooth implant” OR “guided bone regen-
eration” OR “bone regeneration” OR “alveolar ridge augmentation” 
OR “alveolar bone loss” OR “bone resorption” OR “tooth extraction” 
OR “socket preservation” OR “alveolar process” OR “alveolar ridge 
preservation” OR “sinus floor augmentation” OR “sinus lifting” OR 
“sinus lift” OR “maxillary sinus” AND “platelets” OR “platelet- rich 
plasma” OR “PRP” OR “leukocyte platelet plasma” OR “pure platelet- 
rich plasma “OR “P- PRP “OR “LPRP “OR “L- PRP “OR “advanced 
platelet- rich plasma” OR “platelet gel” OR “autogenous cells” OR 
“advanced PRP” OR “A- PRP” OR “APRP” OR “LPRP gel” OR “leuko-
cyte and platelet- rich plasma gel” OR “plasma rich in growth factors”. 
Cochrane search filters for randomized controlled trials (RCTs) and 
CCTs were implemented, with cohort trials also included. The results 
were limited to human studies.
2.4 | Inclusion criteria
1. RCTs or CCTs including at least 10 patients/sites per group.
2. Studies regarding SFE, alveolar ridge preservation, bone augmen-
tation procedures, soft tissue healing or implant therapy com-
bined with PRP.
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2.5 | Exclusion criteria
In vitro and preclinical studies, cohort studies, case series, case 
reports, retrospective studies and RCT or CCT with less than 
10 patients/sites per group and studies not meeting all inclusion 
criteria.
2.6 | Screening and selection of studies
Publication records and titles identified by the electronic search and 
hand search were independently screened by two reviewers (FJS 
and AS), based on the inclusion criteria. No restrictions were applied 
neither for languages, years considered nor for publication status. 
Discrepancies were solved by discussion including a third reviewer 
(RG). Cohen’s Kappa- coefficient was used as a measure of agreement 
between the readers. Thereafter, full texts of the selected abstracts 
were obtained. Where full texts could not be obtained authors and 
editors of the respective journal were contacted. The two review-
ers independently performed the whole screening process, i.e., from 
the MeSH and Emtree term search up to the full- text examination. 
Then, articles that met the inclusion criteria were processed for data 
extraction.
2.7 | Data extraction and quality assessment
The inclusion criteria were applied for data extraction. The stud-
ies were classified according to study design and type of interven-
tion. Then, outcomes were compiled in tables. All extracted data 
were double- checked, and any questions that came up during the 
screening and the data extraction were discussed within the au-
thors to aim for consensus. Two reviewers (FJS and AS) indepen-
dently evaluated the methodological quality of all included studies 
using the Cochrane Collaboration’s tool for assessing risk of bias in 
randomized trials (Higgins et al., 2011). All included studies were 
checked for the following criteria: (a) sequence generation (b) al-
location concealment (c) blinding of participants and personnel (d) 
blinding of outcome assessment (e) incomplete outcome data (f) 
selective reporting (g) other bias. Any disagreement was discussed 
until consensus was achieved. Each study was classified into the 
following groups: low risk of bias if all quality criteria were judged 
as “present”, moderate risk of bias if one or more key domains were 
“unclear”, and high risk of bias if one or more key domains were not 
“present”.
3  | RESULTS
3.1 | Selection of studies
The literature search identified 8,975 potential references in 
Medline and 517 in Embase of which 54 were eligible after title and 
abstract screening (inter- reviewer agreement κ = 0.914 ± 0.059). 
Hand search identified five more studies (Anitua, Murias- Freijo, 
Alkhraisat, & Orive, 2015; Dugrillon, Eichler, Kern, & Kluter, 2002; 
Geurs et al., 2014; Mozzati, Gallesio, di Romana, Bergamasco, & Pol, 
2014; Raghoebar et al., 2005). Of the 59 full- text articles, 27 did not 
meet the inclusion criteria and were excluded (Figure 1; Table 1 of 
excluded studies). The remaining 18 RCTs and 14 CCTs were dis-
cussed in the EAO consensus meeting. Studies dealing with third 
molar extractions were excluded (Table 1). Consequently, 15 RCTs 
and seven CCTs were included for data extraction. The included 
studies were divided into subgroups, depending on the area of PRP 
application (Tables 2–4):
1. SFE (Table 2): n = 12 (Bettega et al., 2009; Cabbar, Guler, Kurkcu, 
Iseri, & Sencift, 2011; Consolo, Zaffe, Bertoldi, & Ceccherelli, 
2007; Del Fabbro, Corbella, Ceresoli, Ceci, & Taschieri, 2015; 
Kumar, Shaik, Nadella, & Chintapalli, 2015; Schaaf, Streckbein, 
Lendeckel, Heidinger, Rehmann, et al., 2008; Schaaf, Streckbein, 
Lendeckel, Heidinger, Gortz, et al., 2008; Stenport, Ortorp, & 
Thor, 2011; Thor, Sennerby, Hirsch, & Rasmusson, 2007; Thor, 
Wannfors, Sennerby, & Rasmusson, 2005; Torres et al., 2009; 
Wiltfang et al., 2003).
2. Alveolar bone regeneration (Table 3a and 3b):
 (a) Alveolar ridge preservation (Table 3a) n = 4 (Alissa, Esposito, 
Horner, & Oliver, 2010; Anitua et al., 2015; Farina, Bressan, Taut, 
Cucchi, & Trombelli, 2013; Mozzati et al., 2014).
 (b) Alveolar ridge augmentation (Table 3b) n = 2 (Eskan et al., 
2014; Torres et al., 2010).
3. Dental implants (Table 4): n = 4 (ArRejaie, Al-Harbi, Alagl, & 
Hassan, 2016; Georgakopoulos et al., 2014; Kundu & Rathee, 
2014; Monov et al., 2005).
3.2 | Exclusion of studies
Exclusion of studies (Table 1) occurred due to: insufficient study co-
hort, missing control group, unavailability of full text, not PRP used 
and application during third molar extraction.
3.3 | Quality assessment of the included studies
Quality and risk assessment was independently conducted 
by two authors (FJS and AS) and are represented in Figures 2 
and 3. Discrepancies were solved by discussion until reaching 
consensus. Included RCTs and CCTs were rated following the 
Cochrane collaboration’s tool for assessing risk of bias. Two 
studies demonstrated low risk of bias for all but one criteria 
and the majority showed a moderate to high risk of bias. Most 
studies failed to provide a detailed report about both rand-
omization and allocation concealment and other key domains 
increasing the risk of bias. Nine studies described the rand-
omization process, 6 the allocation concealment in sufficient 
detail. One study was registered to an online database which 
allows for judgment of selective outcome bias. Adequate blind-
ing of patients and personnel was stated in five trials, blind-
ing of surgeons in four, and blinding of outcome assessors in 
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nine trials. None of the studies provided an intention- to- treat 
analysis of their patients and only four studies described sam-
ple size calculations.
3.4 | Study design and evaluation period
Fifteen RCTs and seven CCTs were included. A total of six studies 
were RCTs where a split- mouth design was applied (ArRejaie et al., 
2016; Bettega et al., 2009; Consolo et al., 2007; Mozzati et al., 2014; 
Schaaf, Streckbein, Lendeckel, Heidinger, Rehmann, et al., 2008; 
Torres et al., 2009) The remaining nine RCTs used a parallel group 
design. Of the CCTs, five were designed as split mouth (Cabbar et al., 
2011; Monov et al., 2005; Stenport et al., 2011; Thor et al., 2005, 
2007), two as parallel group studies (Farina et al., 2013; Kumar et al., 
2015). The follow- up period ranged considerably from 10 days to 
30 months.
3.5 | Subject characteristics
All but one study (Mozzati et al., 2014) included healthy subjects 
with no active inflammatory disease. The mean age varied from 18 
to 80. The number of included patients lied between 10 and 80. 
Smokers were included in eight, excluded in seven and not reported 
in seven studies.
3.6 | Data extraction
Included studies presented a high heterogeneity in regards to out-
come measures, PRP preparation or study duration. Therefore, a 
meta- analysis was not feasible.
3.7 | Sinus floor elevation (totally 374 patients)
All included studies (12) applied PRP in combination with iliac bone 
(seven), autologous intraoral bone grafts (one), β- tricalcium phos-
phate (β- TCP; one), bovine bone graft (BBG) (Unilab Surgibone®/one 
study) and deproteinized bovine bone mineral (DBBM, two). Table 2 
depicts the outcome measures of included studies.
Iliac bone graft (Bettega et al., 2009; Consolo et al., 2007; 
Schaaf, Streckbein, Lendeckel, Heidinger, Rehmann, et al., 2008; 
Schaaf, Streckbein, Lendeckel, Heidinger, Gortz, et al., 2008; 
Stenport et al., 2011; Thor et al., 2005, 2007): no statistical dif-
ferences in resonance frequency analysis values for the poste-
rior maxilla, but significant differences for the anterior maxilla 
F IGURE  1 PRISMA flow diagram
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at abutment connection and at 1- year follow- up was reported by 
one study (Thor et al., 2005). Higher densitometric and trabec-
ular bone values for time- periods up to 6 months were found in 
favor of PRP (Consolo et al., 2007). Thor and coworkers showed 
superiority of bone formation after 3 months for the PRP group, 
which disappeared after 6 months, yet biopsies were not ob-
tained from all patients (Thor et al., 2007). No additive effects 
of PRP were found in survival rate (Thor et al., 2005), augmen-
tation height (Bettega et al., 2009), marginal bone level changes 
(Thor et al., 2005), bone density (Bettega et al., 2009; Schaaf, 
Streckbein, Lendeckel, Heidinger, Rehmann, et al., 2008), volume 
of both lamellar and woven bone (Bettega et al., 2009), volume of 
new bone (Schaaf, Streckbein, Lendeckel, Heidinger, Gortz, et al., 
2008) and angiogenesis (Stenport et al., 2011).
Autologous intraoral bone grafts: In terms of bone height 
after grafting significant differences were found immediately and 
6 months after surgery (Kumar et al., 2015).
Bovine bone graft: there was only one study using BBG (Unilab 
Surgibone®) (Cabbar et al., 2011) and no additional effects of PRP 
were found when looking at implant survival rates, ISQ values, soft 
tissue healing, and histological parameters such as residual amount 
of graft, or trabecular bone structure.
Deproteinized bovine bone mineral: two studies combined 
DBBM with PRP. One study using DBBM demonstrated that PRP 
was associated with significantly less pain and higher quality of life 
parameters post- surgery (Del Fabbro et al., 2015). The other study 
using DBBM showed that PRP significantly increased new bone 
formation (Torres et al., 2009). However, histomorphometric anal-
ysis was only performed in five patients with a split- mouth  design 
and the implant survival rate was not affected by PRP (Torres et al., 
2009).
3.8 | Alveolar ridge preservation (totally 145 
patients)
One study evaluated the use of PRP for ridge preservation. A 
denser trabecular pattern, less pain sensation and better soft tis-
sue healing (Alissa et al., 2010) were reported. Three studies used 
PRGF (Anitua et al., 2015; Farina et al., 2013; Mozzati et al., 2014). 
Anitua et al. (2015) analyzed outcome measures such as regenerated 
socket volume, bone density, soft tissue healing, pain, and histo-
morphometric characteristics like keratinized gingival thickness and 
percentage of new bone formation. The results demonstrated that 
PRGF in mandibular molar extraction sites yielded superior results 
for all assessed outcomes. Superior results for PRGF were described 
in diabetic patients: less pain during the first 14 days and a smaller 
residual socket volume during the first 7 days were observed in the 
test group (Mozzati et al., 2014). However, no differences in terms of 
mineral density and mineralization were described by Farina (Farina 
et al., 2013) (Table 3a).
3.9 | Alveolar ridge augmentation (totally 62 
patients)
Only two studies were found, both of which showed better results 
with PRP. Ridge width at the marginal crest was higher in the PRP 
group as well as the percentage of vital bone (Eskan et al., 2014). 
PRP further enhanced the average gain of bone height and width and 
TABLE  1 List of excluded full- text papers and reasons for 
exclusion following full- text screening
Author and year Reasons for exclusion
Antonello et al. (2013) Third molar extraction
Arenaz- Bua et al. (2010) Third molar extraction
Barbu et al. (2016) Not PRP
Badr et al. (2010) Less than 10 patients per group
Célio- Mariano et al. (2011) Third molar extraction
Cheah et al. (2014) Less than 10 patients per group
Comert et al. (2017) Less than 10 patients per group
Dasmah et al. (2013) No control group
Dugrillon et al. (2002) No control group
Dutta et al. (2015) Third molar extraction
Dutta et al. (2016) Third molar extraction
Garg et al. (2000) No full text available, author so 
far not responding
Gawande et al. (2009) Third molar extraction
Gelbart et al. (2005) No control group
Geurs et al. (2014) Less than 10 patients per group
Kassolis et al. (2005) PRP being not the only variable
Kaul et al. (2012) Third molar extraction
Khairy et al. (2013) Less than 10 patients per group
Kilic et al. (2016) Less than 10 patients per group
Kutkut et al. (2012) PRP being not the only variable
Maiorana et al. (2003) No control group
Malik et al. (2012) No full text available, email of 
author expired
Matsuo et al. (2011) 11 samples taken from only 5 
patients
Mazor et al. (2004) No control group
Menezes et al. (2015) PRP being not the only variable
Mozzati et al. (2010) Third molar extraction
Ntounis et al. (2015) Same study cohort as Geurs 2014
Ogundipe (2011) Third molar extraction
Raghoebar et al. (2005) Insufficient number of patients
Rutkowski et al. (2010) Insufficient number of patients
Sammartino et al. (2003) No control group
Simon et al. (2004) No full text available, email of 
author expired
Steigmann et al. (2005) PRP being not the only variable
Taschieri et al. (2012) Insufficient number of patients
Varghese et al. (2017) Not PRP
Vivek et al. (2009) Third molar extraction
Wallace et al. (2010) No control group
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reduced mesh exposure (Torres et al., 2010). Survival rates were simi-
lar for both groups (Torres et al., 2010), along with greater apical ridge 
width and alveolar height changes (Eskan et al., 2014) (Table 3b).
3.10 | Implant placement (56 patients in three 
studies and one study that did not report the 
number of patients)
Four studies used PRP during implant placement. Only one study 
performed GBR (ArRejaie et al., 2016). PRP enhancing bone forma-
tion was found in two studies (ArRejaie et al., 2016; Georgakopoulos 
et al., 2014). This was associated with larger bone width, higher 
bone density and less marginal bone loss (ArRejaie et al., 2016; 
Georgakopoulos et al., 2014). When looking at implant stability, data 
are scarce (from 40 patients) and pointing toward no differences 
(Kundu & Rathee, 2014; Monov et al., 2005) (Table 4).
4  | DISCUSSION
The present systematic review focused on RCT and CCT stud-
ies using PRP in all fields connected to implant dentistry including 
sinus floor augmentation, socket preservation, ridge augmentation 
or peri- implantitis. The aim was to evaluate the current knowledge 
with respect to the clinical indications of PRP on soft tissue healing 
and bone regeneration with respect to implant placement. Analysis 
of the selected publications revealed heterogeneity of results with a 
general lack of conclusive evidence, mainly because of being under-
powered, and incomplete reporting of study design. Owing to the 
heterogeneity of the study design, the various outcome measures, 
and the slightly different method of preparing PRP, no meta- analysis 
could be performed—neither for bone formation and soft tissue heal-
ing nor for implant stability, osseointegration, and implant survival.
4.1 | Sinus floor elevation
A previous systematic review suggested that PRP might improve SFE 
outcome parameters (Bae, Kim, & Myung, 2011). The present report is 
based on 12 clinical trials when grafting materials were combined with 
PRP. Results are conflicting. PRP increased bone formation and bone 
height in four studies (Kumar et al., 2015; Thor et al., 2007; Torres 
et al., 2009; Wiltfang et al., 2003). These positive findings, however, 
should be interpreted with caution. For example, Kumar et al. de-
scribed a greater bone height in the PRP group immediately after sur-
gery but this difference disappeared at the 12- month follow- up. The 
positive outcome in favor of PRP up to 6 months could be explained 
by the surgical procedure per se rather than the use of PRP. Torres 
et al. reported more bone formation in the PRP group, however, the 
histological analysis included biopsies from only five patients and 
not from the whole sample. All other parameters, including implant 
survival and densitometry, were not significant. Similarly, Thor et al. 
described higher bone formation in the PRP group at the 3- month fol-
low- up, nonetheless, these differences disappeared after 6 months.
In line with these findings, other studies failed to find signifi-
cant differences when using a variety of bone graft materials (au-
tologous bone from the iliac crest, DBBM, BBG, β- TCP), different 
surgical approaches and variable residual bone heights before the 
intervention. In the majority of studies, residual graft size and graft 
resorption were found to be similar among the groups as well as im-
plant survival rates (Cabbar et al., 2011; Kumar et al., 2015; Schaaf, 
Streckbein, Lendeckel, Heidinger, Rehmann, et al., 2008; Thor et al., 
2005; Torres et al., 2009).
Another aspect that was evaluated in two studies was implant 
stability measured by ISQ values (Cabbar et al., 2011; Thor et al., 
2005). While Cabbar et al. found no significant differences, Thor 
F IGURE  2 Quality assessment of the included studies: Risk of 
bias summary
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et al. reported higher ISQ values at abutment connection in the PRP 
group. The latter study performed inlay grafts for SFE and onlay 
grafts for the anterior maxilla followed by implant placement. At 1- 
year follow- up, however, significant differences were detected only 
in the anterior maxilla (Thor et al., 2005). This should be interpreted 
with prudence, as it is questionable if this statistical difference sug-
gests a clinical benefit of PRP. Furthermore, there is a lack of data 
based on the long- term outcomes by means of PRP.
In summary, inconclusive results are reported because of un-
derpowered studies lacking hard endpoints. None of the studies in-
cluded used PRP without a grafting material. Therefore, the effect of 
PRP alone on bone regeneration during SFE remains questionable.
4.2 | PRP and alveolar bone regeneration
Based on the growth factors contained in PRP, filling a post- extraction 
socket with PRP has the potential to improve bone regeneration and 
soft tissue healing. The ultimate goal is to enhance wound healing 
and facilitate implant placement in a prosthetically driven position. 
It should be pointed out that the included studies applied PRP or 
PRGF. Even though both preparations showed beneficial results, 
caution should be taken when drawing a conclusion, as for PRP in 
extraction sockets only one study with a small patient number could 
be included, and for PRGF heterogenous results have been stated. 
PRGF differs from PRP in that it is depleted of leukocytes.
Two studies (Anitua et al., 2015; Farina et al., 2013) reported on 
bone regeneration at extraction sockets using PRGF. In one study 
(Anitua et al., 2015) the use of PRGF enhanced bone regeneration 
defined as the percentage of patients with a regenerated socket 
≥75% at 10–12 weeks. Histomorphometric analysis confirmed the 
greater bone regeneration with PRGF. Farina et al., on the other 
hand, when using PRGF were unable to reproduce these positive 
outcomes in terms of bone volume. This inconsistency may be due 
to the small sample size and shorter follow- up in one of the studies 
and different number or application of membranes and clots (Farina 
et al., 2013). While Anitua et al. included 36 patients in the test 
group, Farina et al. included only 11 patients put into two different 
time points. Anitua et al. performed the analysis after 10–12 weeks 
whereas Farina et al. conducted the analysis after 4–8 weeks. 
Further studies are required to establish the benefit of PRGF and 
PRP for this clinical indication.
Three studies (Alissa et al., 2010; Anitua et al., 2015; Mozzati 
et al., 2014) reported outcomes using a soft tissue healing index. PRP 
improved wound and soft tissue healing during the first 15 days. An 
interesting approach was carried out by Mozzatti et al. in insulin- 
dependent patients. The use of PRGF improved the wound healing 
during the first 2 weeks. In this context, PRGF might be an attrac-
tive approach in systemically compromised patients to achieve rapid 
wound healing. Nevertheless, the clinical interpretation is difficult 
due to the plethora of healing indexes not commonly used.
Two of the aforementioned studies (Alissa et al., 2010; Anitua 
et al., 2015) further provided positive outcomes of bone density 
measured by radiographs and cone beam computer tomography at 
3 months. However, bone density is not a suitable outcome for alveo-
lar ridge preservation or at least it is difficult to interpret from a clinical 
point of view. Thus, there is great necessity for appropriately designed 
studies to further evaluate dimensional changes utilizing PRP in var-
ious clinical situations considering medically compromised patients.
Two studies reported on alveolar ridge augmentation procedures 
with PRP (Eskan et al., 2014; Torres et al., 2010) detecting beneficial 
results such as increased crestal ridge width, a higher percentage of 
vital bone, higher gain of bone height and width and less mesh expo-
sure. Eskan et al. showed a significant higher value for ridge width at 
the crest in the test group, but they did not provide detailed infor-
mation about the initial bone volume deficiency. Torres et al. showed 
gain of bone height and width, however, the additional bone gain in 
the PRP group was only about 0.4 mm. Patients enrolled had insuf-
ficient bone height of up to 7 mm and/or bone width of up to 3 mm. 
The lack of detailed data in both studies precludes a comprehensive 
comparison of the results. One noteworthy finding, however, was 
the absence of titanium mesh exposure in the PRP group compared 
to 28.5% in the control group (Torres et al., 2010). Overall, given the 
low number of studies and the different surgical approaches used, it 
is difficult to generate clinical recommendations.
F IGURE  3 Quality assessment of the included studies: Risk of bias graph
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4.3 | PRP and pain
Pain is an important patient- reported outcome measure and significantly 
determines the quality of patient’s oral surgery experience (Coulthard, 
Patel, Bailey, & Armstrong, 2014). Three studies included patient- 
reported outcome measures, mainly using the Visual Analogue Scale. 
However, the positive effect of PRP on postoperative pain was consid-
ered biased in two of three studies due to lack of blinding. All outcomes 
can be affected by lack of blinding as there is a special risk of bias with 
subjective outcomes such as pain (Wood et al., 2008). Consequently, 
the present data must be interpreted with caution. Significantly less 
pain was reported in the PRP group for SFE (Del Fabbro et al., 2015) and 
for alveolar ridge preservation (Alissa et al., 2010; Anitua et al., 2015). 
Del Fabbro et al. showed a significant difference in SFE only after 2 and 
3 days. From the 4th day on, the significant difference disappeared, 
which is in line with the results from Alissa et al. who detected differ-
ences between the groups only until the 3rd day post- op while Anitua 
et al. observed less pain during the first 7 days in the PRGF group. In 
summary, owing to study design there is not enough evidence to sup-
port that PRP reduces pain after the surgical procedure.
Another aspect that should be considered is the postoperative 
swelling. Only one study assessed swelling after sinus lift elevation 
(Del Fabbro et al., 2015). Patients in the PRP group perceived less 
swelling during the first 4 days postoperatively. However, this pa-
rameter was measured using a self- administered questionnaire. As a 
result, more studies are warranted.
4.4 | Dental implants
With respect to PRP application during implant placement, only 
three RCTs and 1 CCT were included. Two studies assessed implant 
stability at different time- points with inconsistent results (Kundu & 
Rathee, 2014; Monov et al., 2005). Only one study found significant 
higher ISQ values in the PRP group at implant placement (Kundu & 
Rathee, 2014) that were no longer present after 1 and 3 months. PRP 
was found to provide a higher bone width, higher bone density, and 
less marginal bone resorption at 9 and 12 months (ArRejaie et al., 
2016). Despite these positive findings, it remains unclear if PRP pre-
dictably improves osseointegration, implant success and survival.
4.5 | Peri- implantitis
Regarding the application of PRP during peri- implantitis treatment, 
no RCT or CCT could be found in the present systematic review. 
Thus, it remains unknown what effect PRP may play in the treatment 
of peri- implantitis, precluding any clinical recommendation.
5  | CONCLUSION
On the basis of studies with limited statistical power, the present re-
view demonstrated that (i) for SFE PRP/PRGF combined with graft-
ing materials may transiently enhance bone formation, (ii) for alveolar 
ridge preservation PRP/PRGF might improve bone regeneration and 
wound healing, (iii) PRP might reduce postoperative pain and swell-
ing, and finally (iv) for implant placement and peri- implantitis defects 
there is a lack of adequate studies on PRP.
6  | FUTURE DIREC TION
The studies included in the present review mainly focused on surro-
gate parameters to evaluate the effect of PRP. The clinical relevance 
of the outcome measurements remains questionable. A low number 
of studies were found to be included for PRP during implant place-
ment and ridge augmentation. An interesting aspect that requires 
further attention is to investigate what effects PRP might bring 
under demanding clinical situation, for example in medically com-
promised patients or in extraction sockets with severe buccal bone 
deficiency. One area of research that needs to be determined is for 
which clinical settings PRP should be used alone or in combination 
with grafting materials. In order to provide the clinicians with data 
or even guidelines whether to use PRP or not, in which clinical situ-
ations and for what kind of patients further well- designed RCTs are 
warranted.
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